US FDA allows companies to distribute articles on off-label use
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has finalised controversial guidance that permits drug and medical device manufacturers to disseminate information to healthcare professionals on the off-label uses of their approved products by reprinting articles in medical and scientific journals1,2. The document contains recommendations outlining the approach that the agency wants companies to follow in printing and distributing such articles.